PIA
LCTX icon

Peachtree Investment Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Peachtree Investment Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-2,478
Closed -$7K – 189
2015
Q2 		$7K Hold
2,478
– – 0.01% 263
2015
Q1 		$10K Hold
2,478
– – 0.01% 265
2014
Q4 		$7K Hold
2,478
– – ﹤0.01% 307
2014
Q3 		$6K Buy
+2,478
New +$5.96K ﹤0.01% 323

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Peachtree Investment Advisors's LCTX Position: Q3 2015 in Review

Peachtree Investment Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2015, closing a stake of 2,478 shares — an estimated $7K sold.

Peachtree Investment Advisors first reported a position in LCTX in Q3 2014 and held it in 4 quarters. The position peaked at $10K in Q1 2015. 74 funds tracked by Wall St. Rank hold LCTX as of Q3 2015.

  • Peachtree Investment Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Peachtree Investment Advisors sold 2,478 Lineage Cell Therapeutics shares in Q3 2015, an estimated $7K.
  • Peachtree Investment Advisors first reported a position in Lineage Cell Therapeutics in Q3 2014 and held it in 4 quarters.
  • Peachtree Investment Advisors's Lineage Cell Therapeutics position peaked at $10K in Q1 2015.
  • 74 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2015.

Based on Peachtree Investment Advisors's 13F filing for Q3 2015, filed 14 Oct 2015.